Akihiko Gemma

Analysis File of Drug-Induced Lung Injury

Expert Opinion for Analysis of Big Data

• Gebundenes Buch

Produktbeschreibung

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshingalternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Nankodo Co., Ltd. / Springer / Springer Nature Singapore / Springer, Berlin
• Artikelnr. des Verlages: 978-981-97-3445-0
• 2024
• Seitenzahl: 128
• Erscheinungstermin: 2. August 2024
• Englisch
• Abmessung: 241mm x 160mm x 13mm
• Gewicht: 389g
• ISBN-13: 9789819734450
• ISBN-10: 9819734452
• Artikelnr.: 70394389

Autorenporträt

¿Akihiko Gemma President, Nippon Medical School 1983: Graduated from the Faculty of Medicine of Nippon Medical School 1986: Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute 1989: Graduated from Nippon Medical School Graduate School 1995: Studied at National Cancer Institute of National Institutes of Health (NIH), the United States 1998: Appointed as a lecturer to Nippon Medical School 2004: Appointed as an associate professor 2008: Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division) 2012: Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine 2013: Appointed dean of Department of Medicine 2015¿ Appointed president

Inhaltsangabe

Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).